Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007070860> ?p ?o ?g. }
- W2007070860 endingPage "616" @default.
- W2007070860 startingPage "608" @default.
- W2007070860 abstract "Purpose Prostate cancer patients exhibit variability in normal tissue reactions and biochemical failure. With the use of image-guided radiotherapy (IGRT), there is a greater likelihood that the differences in normal tissue and tumor response are due to biological rather than physical factors. We tested the hypothesis that prospectively scored acute toxicity is associated with biochemical failure-free rate (BFFR) in prostate cancer patients treated with IGRT. Methods and Materials We retrospectively analyzed BFFR in 362 patients with localized prostate cancer treated with IGRT. We compared BFFR with prospectively collected Radiation Therapy Oncology Group (RTOG) maximum acute gastrointestinal (GI) and genitourinary (GU) toxicity scores. Median follow-up for all patients was 58.3 months after total radiotherapy doses of 75.6–79.8 Gy. Results Patients reporting RTOG acute GU or GI toxicity scores of ≥2 were considered “sensitive” (n = 141, 39%) and patients reporting scores <2 were considered “nonsensitive” (n = 221, 61%). When calculating biochemical failure (BF) using the American Society for Therapeutic Radiology and Oncology definition at 5 years, 76% (CI 70–82%) of the “nonsensitive” patients were failure free, compared with only 53% (CI 43–62%) of the “sensitive” patients (log–rank test, p < 0.0001). This difference was also observed using the Phoenix definition; “nonsensitive” 5-year BFFR was 81% (CI 74–86%) vs. “sensitive” BFFR was 68% (CI 58–76%; log–rank test p = 0.0012). The difference in BF between cohorts remained significant when controlled for radiation dose (75.6 vs. 79.8 Gy), prognostic stratification (T category, prostate-specific antigen, and Gleason score), and prostate volume. Conclusions This study unexpectedly shows that prostate cancer patients who develop ≥Grade 2 RTOG acute toxicity during radiotherapy are less likely to remain BFF at 5 years. These results deserve further study and, if validated in other large IGRT cohorts, additional models would be required to study interaction between normal tissue and tumor biology in prostate cancer patients. Prostate cancer patients exhibit variability in normal tissue reactions and biochemical failure. With the use of image-guided radiotherapy (IGRT), there is a greater likelihood that the differences in normal tissue and tumor response are due to biological rather than physical factors. We tested the hypothesis that prospectively scored acute toxicity is associated with biochemical failure-free rate (BFFR) in prostate cancer patients treated with IGRT. We retrospectively analyzed BFFR in 362 patients with localized prostate cancer treated with IGRT. We compared BFFR with prospectively collected Radiation Therapy Oncology Group (RTOG) maximum acute gastrointestinal (GI) and genitourinary (GU) toxicity scores. Median follow-up for all patients was 58.3 months after total radiotherapy doses of 75.6–79.8 Gy. Patients reporting RTOG acute GU or GI toxicity scores of ≥2 were considered “sensitive” (n = 141, 39%) and patients reporting scores <2 were considered “nonsensitive” (n = 221, 61%). When calculating biochemical failure (BF) using the American Society for Therapeutic Radiology and Oncology definition at 5 years, 76% (CI 70–82%) of the “nonsensitive” patients were failure free, compared with only 53% (CI 43–62%) of the “sensitive” patients (log–rank test, p < 0.0001). This difference was also observed using the Phoenix definition; “nonsensitive” 5-year BFFR was 81% (CI 74–86%) vs. “sensitive” BFFR was 68% (CI 58–76%; log–rank test p = 0.0012). The difference in BF between cohorts remained significant when controlled for radiation dose (75.6 vs. 79.8 Gy), prognostic stratification (T category, prostate-specific antigen, and Gleason score), and prostate volume. This study unexpectedly shows that prostate cancer patients who develop ≥Grade 2 RTOG acute toxicity during radiotherapy are less likely to remain BFF at 5 years. These results deserve further study and, if validated in other large IGRT cohorts, additional models would be required to study interaction between normal tissue and tumor biology in prostate cancer patients." @default.
- W2007070860 created "2016-06-24" @default.
- W2007070860 creator A5000970066 @default.
- W2007070860 creator A5006543032 @default.
- W2007070860 creator A5020744487 @default.
- W2007070860 creator A5027354813 @default.
- W2007070860 creator A5037763217 @default.
- W2007070860 creator A5042842956 @default.
- W2007070860 creator A5061721154 @default.
- W2007070860 creator A5064900626 @default.
- W2007070860 creator A5070759426 @default.
- W2007070860 creator A5078348186 @default.
- W2007070860 creator A5079599136 @default.
- W2007070860 creator A5085843671 @default.
- W2007070860 creator A5091336952 @default.
- W2007070860 creator A5091737661 @default.
- W2007070860 date "2012-06-01" @default.
- W2007070860 modified "2023-10-07" @default.
- W2007070860 title "Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer" @default.
- W2007070860 cites W1510003450 @default.
- W2007070860 cites W1980630930 @default.
- W2007070860 cites W1981401469 @default.
- W2007070860 cites W2002304475 @default.
- W2007070860 cites W2004246843 @default.
- W2007070860 cites W2009212279 @default.
- W2007070860 cites W2012276721 @default.
- W2007070860 cites W2016899305 @default.
- W2007070860 cites W2018825948 @default.
- W2007070860 cites W2025895255 @default.
- W2007070860 cites W2030589943 @default.
- W2007070860 cites W2031262827 @default.
- W2007070860 cites W2039425935 @default.
- W2007070860 cites W2039846010 @default.
- W2007070860 cites W2043945205 @default.
- W2007070860 cites W2046932097 @default.
- W2007070860 cites W2050517163 @default.
- W2007070860 cites W2071120462 @default.
- W2007070860 cites W2076795607 @default.
- W2007070860 cites W2088617308 @default.
- W2007070860 cites W2089502905 @default.
- W2007070860 cites W2093867637 @default.
- W2007070860 cites W2099798423 @default.
- W2007070860 cites W2102550616 @default.
- W2007070860 cites W2104220131 @default.
- W2007070860 cites W2104729954 @default.
- W2007070860 cites W2105364421 @default.
- W2007070860 cites W2105475002 @default.
- W2007070860 cites W2106986203 @default.
- W2007070860 cites W2108424994 @default.
- W2007070860 cites W2111382211 @default.
- W2007070860 cites W2117204935 @default.
- W2007070860 cites W2117792530 @default.
- W2007070860 cites W2118315717 @default.
- W2007070860 cites W2123519431 @default.
- W2007070860 cites W2135997039 @default.
- W2007070860 cites W2141680420 @default.
- W2007070860 cites W2148539277 @default.
- W2007070860 cites W2151325774 @default.
- W2007070860 cites W2155480439 @default.
- W2007070860 cites W2163267999 @default.
- W2007070860 cites W2165736769 @default.
- W2007070860 cites W2166266771 @default.
- W2007070860 cites W2166283970 @default.
- W2007070860 cites W2171882815 @default.
- W2007070860 cites W4234506270 @default.
- W2007070860 doi "https://doi.org/10.1016/j.ijrobp.2011.07.019" @default.
- W2007070860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22099034" @default.
- W2007070860 hasPublicationYear "2012" @default.
- W2007070860 type Work @default.
- W2007070860 sameAs 2007070860 @default.
- W2007070860 citedByCount "9" @default.
- W2007070860 countsByYear W20070708602013 @default.
- W2007070860 countsByYear W20070708602016 @default.
- W2007070860 countsByYear W20070708602017 @default.
- W2007070860 countsByYear W20070708602018 @default.
- W2007070860 countsByYear W20070708602020 @default.
- W2007070860 countsByYear W20070708602022 @default.
- W2007070860 crossrefType "journal-article" @default.
- W2007070860 hasAuthorship W2007070860A5000970066 @default.
- W2007070860 hasAuthorship W2007070860A5006543032 @default.
- W2007070860 hasAuthorship W2007070860A5020744487 @default.
- W2007070860 hasAuthorship W2007070860A5027354813 @default.
- W2007070860 hasAuthorship W2007070860A5037763217 @default.
- W2007070860 hasAuthorship W2007070860A5042842956 @default.
- W2007070860 hasAuthorship W2007070860A5061721154 @default.
- W2007070860 hasAuthorship W2007070860A5064900626 @default.
- W2007070860 hasAuthorship W2007070860A5070759426 @default.
- W2007070860 hasAuthorship W2007070860A5078348186 @default.
- W2007070860 hasAuthorship W2007070860A5079599136 @default.
- W2007070860 hasAuthorship W2007070860A5085843671 @default.
- W2007070860 hasAuthorship W2007070860A5091336952 @default.
- W2007070860 hasAuthorship W2007070860A5091737661 @default.
- W2007070860 hasConcept C116263406 @default.
- W2007070860 hasConcept C121608353 @default.
- W2007070860 hasConcept C126322002 @default.
- W2007070860 hasConcept C126894567 @default.
- W2007070860 hasConcept C133507102 @default.
- W2007070860 hasConcept C143998085 @default.